A Look at the Broadly Neutralizing Antibody Pipline- What Happens After AMP

Devin Sok, Direction of Antibody Discovery and Development, and Olayinka Fagbayi, Program Director Neutralizing Antibody Center, of IAVI will discuss the antibody pipeline. They will review how IAVI is planning for the results of the AMP trial, the first proof-of-concept study of broadly neutralizing antibodies for HIV prevention, expected to be released in 2020. The pair will answer questions from advocates about the future of the bNAbs and their potential to impact the HIV prevention landscape.